V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Viking Therapeutics Executive Compensation (FY25)

VKTX · Executive and director compensation, fiscal 2023 to 2025

The paid brief on Viking Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 19, 2026Latest filing (8-K): May 26, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Viking Therapeutics brief$1,500Get the executive brief
202 figures on this page: 196 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Brian Lian
Latest say-on-pay support
=
May 19, 2026

More on Viking Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Brian Lian: $14,298,554 → $21,269,833 (48.8% higher)
Say-on-pay support: 66.9% → 70.2% (3.3 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Viking Therapeutics' chief executive and what were they paid?
Brian Lian was paid $21,269,833 in total compensation as Chief Executive Officer for fiscal 2025. Lian's total moved 48.8% higher from the $14,298,554 reported for fiscal 2024.
What was Viking Therapeutics' say-on-pay result?
The say-on-pay proposal drew 70.2% of votes cast for or against in favor at the meeting held May 19, 2026 for fiscal 2025.
Which companies are in Viking Therapeutics' peer group?
Companies named in the disclosed peer group include Akero Therapeutics, Inc., Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Avidity Biosciences, Inc. and BridgeBio Pharma, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Lian
Chief Executive Officer
◇—◇◇◇——◇
Marianne Mancini
Chief Operating Officer
◇—◇◇◇——◇
Greg Zante
Chief Financial Officer
◇—◇◇◇——◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Lian
Chief Executive Officer
◇—◇◇◇—◇◇
Marianne Mancini
Chief Operating Officer
◇—◇◇◇——◇
Greg Zante
Chief Financial Officer
◇—◇◇◇——◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Lian
Chief Executive Officer
◇—◇◇◇——◇
Marianne Mancini
Chief Operating Officer
◇—◇◇◇——◇
Greg Zante
Chief Financial Officer
◇—◇◇◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brian LianRSU◇——◇——◇
Brian LianPSU◇—◇—◇—◇
Brian LianOPTION◇——◇—◇◇
Greg ZantePSU◇—◇—◇—◇
Greg ZanteOPTION◇——◇—◇◇
Greg ZanteRSU◇——◇——◇
Marianne ManciniPSU◇—◇—◇—◇
Marianne ManciniRSU◇——◇——◇
Marianne ManciniOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Greg ZanteOption◇—◇—
Option◇—◇—
Option◇—◇—
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
Marianne ManciniOption◇—◇—
Option◇—◇—
Option◇—◇—
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
Brian LianOption◇—◇—
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
S. Kathryn Rouan, Ph.D
◇—◇——◇◇
S. Kathryn Rouan
◇—◇——◇◇
Lawson Macartney, B.V.M.S., Ph.D
Board chair
◇—◇——◇◇
J. Matthew Singleton
◇—◇———◇
Charles A. Rowland Jr
◇—◇———◇
Matthew W. Foehr
◇—◇———◇
Brian Lian, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Akero Therapeutics, Inc. AKRO
  • Amicus Therapeutics, Inc. FOLD
  • Arrowhead Pharmaceuticals, Inc. ARWR
  • Avidity Biosciences, Inc. AVID
  • BridgeBio Pharma, Inc. symbol not shown
  • Crinetics Pharmaceuticals, Inc. CRNX
  • Cytokinetics, Incorporated CYTK
  • Dyne Therapeutics, Inc. symbol not shown
  • Intra-Cellular Therapies, Inc. ICLR
  • Krystal Biotech Inc. symbol not shown
  • Madrigal Pharmaceuticals, Inc. MDGL
  • Protagonist Therapeutics Inc. symbol not shown
  • Revolution Medicines, Inc. RVMD
  • Rhythm Pharmaceuticals Inc. RYTM
  • SpringWorks Therapeutics, Inc. symbol not shown
  • Summit Therapeutics Inc. SMMT
  • United Therapeutics Corporation UTHR
  • Vaxcyte, Inc. symbol not shown

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 19, 2026=◇◇◇
2024May 20, 2025=◇◇◇
2023May 21, 2024=◇◇◇
2022June 13, 2023=◇◇◇
2021May 24, 2022=◇◇◇
2020May 20, 2021=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Viking Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Viking Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Viking Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Viking Therapeutics' disclosed peer group is defensible, who names Viking Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
202 figures on this page: 196 cited to the filing that reported them, 6 calculated from figures it prints.
196 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001193125-26-239535
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-137915
    Grants of Plan-Based Awards
  3. 0000950170-25-077865
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000950170-25-052162
    Summary Compensation Table
  5. 0000950170-24-063707
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000950170-24-042251
    Summary Compensation Table
  7. 0000950170-23-027965
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001564590-22-021417
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001564590-21-029335
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Viking Therapeutics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/VKTX (accessed 2026).
Short form: data: Velarion

The paid brief for Viking Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Viking Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Viking Therapeutics discloses

The companies named in VKTX's own disclosed peer group.

Akero Therapeutics, Inc.Amicus Therapeutics, Inc.Arrowhead Pharmaceuticals, Inc.Avidity Biosciences, Inc.Crinetics Pharmaceuticals, Inc.Cytokinetics, IncorporatedMadrigal Pharmaceuticals, Inc.Revolution Medicines, Inc.Rhythm Pharmaceuticals Inc.Summit Therapeutics Inc.United Therapeutics Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy